Ipilimumab at 3 mg/kg compared with HDI showed an improved 5-year OS of 72% versus 67% (hazard ratio (HR) 0.78, 95% confidence interval (CI) 0.61–0.99, p -value 0.044), and the benefit of ipilimumab at 10 mg/kg over HDI did not reach statistical significance.
← all excerpts
Treatment Approaches for Melanomas That Relapse After Adjuvant or Neoadjuvant Therapy.
1
—
—